Clinical Study to Assess the Effect of Food on the Pharmacokinetic Characteristics of CKD-501 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 13 Dec 2010
At a glance
- Drugs Lobeglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Acronyms CKD-501 FDI
- 13 Dec 2010 Planned End Date changed from 1 Aug 2010 to NULL.
- 13 Dec 2010 Planned initiation date changed from 1 Mar 2010 to NULL.
- 09 Dec 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.